| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.12 | 3e-05 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | 0.16 | 3e-05 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.21 | 0.0001 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0002 |
| mRNA | LY317615 | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0003 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0004 |
| mRNA | Gemcitabine | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0005 |
| mRNA | GDC-0941 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0007 |
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | 0.094 | 0.001 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | 0.099 | 0.002 |